BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Beezer J, Al Hatrushi M, Husband A, Kurdi A, Forsyth P. Polypharmacy definition and prevalence in heart failure: a systematic review. Heart Fail Rev 2021. [PMID: 34213753 DOI: 10.1007/s10741-021-10135-4] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
Number Citing Articles
1 Stefil M, Dixon M, Bahar J, Saied S, Mashida K, Heron O, Shantsila E, Walker L, Akpan A, Lip GY, Sankaranarayanan R. Polypharmacy in Older People With Heart Failure: Roles of the Geriatrician and Pharmacist. Card Fail Rev 2022. [DOI: 10.15420/cfr.2022.14] [Reference Citation Analysis]
2 Dautzenberg L, Numan L, Knol W, Gianoli M, van der Meer MG, Troost-oppelaar A, Westendorp AF, Emmelot-vonk MH, van Laake LW, Koek HL. Hyperpolypharmacy is a predictor of mortality after left ventricular assist device (LVAD) implantation. American Heart Journal Plus: Cardiology Research and Practice 2022;24:100233. [DOI: 10.1016/j.ahjo.2022.100233] [Reference Citation Analysis]
3 Sefera B, Getachew M, Babu Y, Bekele F, Fanta K. Drug-related problems and its predictors among hospitalized heart failure patients at Jimma Medical Center, South West Ethiopia: prospective interventional study. BMC Cardiovasc Disord 2022;22:418. [PMID: 36123632 DOI: 10.1186/s12872-022-02859-4] [Reference Citation Analysis]
4 Irabor B, Mcmillan JM, Fine NM. Assessment and Management of Older Patients With Transthyretin Amyloidosis Cardiomyopathy: Geriatric Cardiology, Frailty Assessment and Beyond. Front Cardiovasc Med 2022;9. [DOI: 10.3389/fcvm.2022.863179] [Reference Citation Analysis]